top of page

What Is Tesamorelin? Growth Hormone & Visceral Fat Research

Oct 24
4 min read

Updated: 7 days ago


You've probably heard about Retatrutide for weight-loss research or BPC-157 in conversations about recovery.


But there's another peptide that gets plenty of attention in fitness and biohacking communities: tesamorelin, commonly called TESA.


Unlike GLP-1 compounds that influence appetite, Tesamorelin works through the body's growth hormone system.


It's particularly interesting because researchers have studied its relationship with visceral fat, the fat stored deep inside the abdomen. So, how does tesamorelin work? Does it build muscle? And what does the science actually show?


In this guide, Ramos Method, based in Calgary, Alberta, breaks down Tesamorelin research in simple terms.


What Is Tesamorelin?


Tesamorelin is a synthetic growth hormone-releasing factor (GHRF) analogue.


It is designed to stimulate the pituitary gland, a small structure located at the base of the brain.

The pituitary gland naturally releases growth hormone, which plays a role in metabolism, body composition, and tissue maintenance.

Tesamorelin acts through this existing hormonal pathway rather than supplying growth hormone directly.

This distinction is what makes it different from many other peptides commonly discussed in fitness research.


How Does Tesamorelin Work?


The science becomes easier to understand when broken into three steps.


Step 1: Pituitary Stimulation


Tesamorelin activates receptors involved in growth hormone release.


Step 2: Growth Hormone Signaling


The pituitary responds by releasing growth hormone, which influences several metabolic processes.


Step 3: IGF-1 Production


Growth hormone stimulates the production of insulin-like growth factor 1 (IGF-1), particularly in the liver.

IGF-1 contributes to growth-related signaling and tissue metabolism.

Researchers are interested in how these hormonal changes affect fat distribution, metabolic health, and body composition.


Tesamorelin and Visceral Fat Research


This is where tesamorelin becomes especially interesting.

Not all body fat is stored in the same place.


Subcutaneous fat sits directly beneath the skin.


Visceral fat surrounds internal organs deep within the abdominal cavity.


Excess visceral fat is associated with increased metabolic and cardiovascular risks.

Clinical studies have investigated whether tesamorelin can reduce visceral fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat distribution.


These studies found reductions in visceral abdominal fat, generally around 15% over 26 weeks in the studied populations.


Does Tesamorelin Build Muscle?


This is one of the most common questions in fitness communities.

Growth hormone and IGF-1 are involved in processes related to tissue growth and metabolism.

Because tesamorelin stimulates this hormonal system, it has attracted interest among researchers studying body composition.


Clinical research has primarily focused on changes in fat distribution rather than proving muscle-building benefits in healthy gym-goers.


Tesamorelin vs Retatrutide: What's the Difference?


Although both compounds appear in metabolic research discussions, their mechanisms are very different.

Feature

Tesamorelin

Retatrutide

Research category

Growth hormone signaling

Metabolic hormone signaling

Primary targets

GHRF receptors

GLP-1, GIP and glucagon receptors

Main clinical research

Excess visceral fat

Obesity and metabolic conditions

Effect on appetite

Not its primary mechanism

Appetite regulation is a key mechanism

Research interest

Fat distribution and GH/IGF-1

Body weight and metabolic regulation


The takeaway: Tesamorelin works through the growth hormone pathway, while retatrutide activates three metabolic hormone receptors.


What Are the Potential Side Effects?


Because tesamorelin affects growth hormone and IGF-1 signaling, researchers and clinicians monitor several potential effects.

Reported concerns include:


  • Fluid retention and swelling

  • Joint or muscle discomfort

  • Changes in blood glucose regulation

  • Elevated IGF-1 levels

  • Injection-site reactions



Frequently Asked Questions About Tesamorelin


Is tesamorelin the same as HGH?


No. Human growth hormone (HGH) is the hormone itself. Tesamorelin stimulates the pituitary gland to release growth hormone.


Does tesamorelin target belly fat?


Clinical studies have demonstrated reductions in visceral abdominal fat in adults.


Is tesamorelin a GLP-1 peptide?


No. Tesamorelin works through growth hormone-releasing factor receptors, while GLP-1 medications activate metabolic hormone receptors.


What is IGF-1?


IGF-1 stands for insulin-like growth factor 1. It is a hormone involved in growth and metabolic signaling that is influenced by growth hormone.


Final Thoughts: Why Tesamorelin Is Interesting


Tesamorelin stands apart from many popular research peptides because of its direct relationship with the growth hormone system.


Clinical studies have demonstrated measurable effects on visceral fat in a specific patient population.


Its relationship with growth hormone, IGF-1, and body composition continues to make it an interesting compound in metabolic research.


Explore Growth Hormone Research With Ramos Method Calgary


At Ramos Method, we make peptide research easier to understand.


Based in Calgary, Alberta, our educational resources cover growth hormone signaling, metabolic research, laboratory testing, and emerging peptide compounds.


Our research library explores tesamorelin alongside other compounds frequently discussed in fitness and longevity communities.Ramos Method also works with ACS Labs in Florida for analytical testing and Certificates of Analysis.


These reports help document the characteristics of tested materials, including identity and purity measurements where performed.


Explore the Ramos Method research library to learn more about peptide science, laboratory transparency, and current research developments.


Ramos Method | Calgary, Alberta, Canada

Educational information only. This article is not medical advice.


Selected Research References

Falutz J, et al. (2007)

Metabolic Effects of a Growth Hormone-Releasing Factor in Patients With HIV.

New England Journal of Medicine.

U.S. Food and Drug Administration

Egrifta WR: Tesamorelin Prescribing Information.

Health Canada

Drug Product Database: Egrifta.

Comments


bottom of page